洞察行业痛点：传统冲刷方式的局限 在智能马桶的普及过程中，消费者普遍面临 " 噪音大、冲刷不彻底 " 等使用痛点。传统直冲式马桶 虽能快速带走污物，但水流冲击易造成喷溅，且噪音较大；虹吸式马桶依靠负压原理清除污物，虽 有效但同样伴随明显声响。这些不足在一定程度上制约了用户体验和行业升级。 近日，艾瑞咨询基于对智能马桶行业的深度研究与技术分析，正式授予九牧集团 " 全球首创智 能马桶翻转冲刷技术 " 认证。该认证聚焦产品工艺创新、技术创新与行业影响力等维度，通过 严谨的行业市场调研、全球在售智能马桶的对比分析、专家访谈、大数据监测，充分肯定九牧 智能马桶在推动智能马桶品类升级中的里程碑意义。 作为深耕卫浴行业 35 年的龙头企业，九牧集团始终坚持运用先进的数字化与人工智能技术，重视 工厂的智能化建设，实现了研发、生产、营销与管理等全业务流程的数智化。目前，九牧集团在全 球范围拥有 15 家高端数智工厂组成的工厂集群体系，涵盖了智能马桶、五金、陶瓷、浴室柜与橱 柜等各个品类，为产品研发和产业升级提供了坚实支撑。 技术引领行业：翻转冲刷的革命性突破 在核心产品技术上，九牧集团持续保持原创性和领先性。其自主研发的翻转 ...

Core Viewpoint - Ruiang Gene reported a decline in revenue and net profit for the first half of 2025, attributed to intensified competition in the in vitro diagnostics industry, executive events, and the cancellation of VAT tax incentives, while maintaining a high level of R&D investment [2][3] Group 1: Financial Performance - The company achieved revenue of 105 million yuan and a net profit attributable to shareholders of 3.5543 million yuan in the first half of 2025 [2] - R&D investment amounted to 31.6472 million yuan, representing 30.21% of the revenue, which is considered high within the industry [2] Group 2: Product Development and Market Expansion - Despite the revenue decline, the company made significant progress in product admissions, with 45 new hospital admissions for core products in the first half of 2025 [4] - Specific product admissions included 20 for leukemia products, 18 for lymphoma products, and 6 for WT1 products, indicating a strong pipeline for future growth [4] Group 3: Technological Advancements - The company has made notable advancements in digitalization and AI technology applications, particularly in the field of hematological tumors, leveraging a large database of over 200,000 annual blood tumor detection data [3] - A big data platform has been established to process vast amounts of research sample data, utilizing AI algorithms to explore potential tumor signaling pathways and treatment targets [3] Group 4: Subsidiary Performance - The company’s subsidiary, Shanghai Sitai Medical Testing Laboratory, successfully passed the CAP (College of American Pathologists) on-site review, indicating high standards in quality management [4][5] - Additionally, the subsidiary Yuanqi Bio added 10 new first-class medical device registration products in the first half of 2025 [5]